API | vapendavir

vapendavir Report issue

Small molecule Experimental

AACT DrugBank PubChem

Active Ingredient History

NOW

Now

Chemistry

SMILES: CCOc1noc2cc(OCCC3CCN(c4ccc(C)nn4)CC3)ccc12
InChIKey: DKSVBVKHUICELN-UHFFFAOYSA-N
Mol. Mass: 382.46
ALogP: 4.01 Partition coefficient
ChEMBL Molecule:
vapendavir

More Chemistry

Pharmacology

Mechanisms of Action:
- VP1 capsid protein (Human rhinovirus 1A) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

bta798 | vapendavir

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (13)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (13)

Asthma (Phase 2)

Enterovirus (Phase 2)

Enterovirus Infections (Phase 2)

Healthy Volunteers (Phase 1)

Infections (Phase 2)

Lung Diseases (Phase 2)

Lung Diseases, Obstructive (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Respiratory Tract Diseases (Phase 2)

Respiratory Tract Infections (Phase 2)

Rhinovirus (Phase 2)

RNA Virus Infections (Phase 2)

Virus Diseases (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 8
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue